Lundbeck Opens $7.6 Million Production Plant in Tianjin

Lundbeck A/S, the Danish CNS drugmaker, has opened a $7.6 million production plant in Tianjin, its first manufacturing facility in China. Lundbeck has been marketing its products in China for sixteen years. In 2010, Lundbeck opened an R&D center in Shanghai. The new Tianjin facility will initially manufacture the company’s treatment for Alzheimer’s disease, Ebixa. More details.... Stock Symbol: (CPH: LUN ) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});